Signals
12IgG4-related disease enters real prescribing territory
Inebilizumab IgG4-RD pivotal data, rituximab maintenance protocols, and structured diagnostic pathways are reshaping IgG4-related disease management.
Systemic sclerosis therapy options mature past hematopoietic stem cell transplant
Tocilizumab and nintedanib in SSc-ILD, anifrolumab pivotal data, and emerging mechanism-targeted programs are reshaping systemic sclerosis management.
Giant cell arteritis therapy options widen past corticosteroids
Tocilizumab maturity, secukinumab pivotal data, and emerging mechanism-targeted programs are reshaping giant cell arteritis management.
ANCA-associated vasculitis therapy options mature around avacopan
Avacopan commercial maturity, rituximab maintenance protocols, and emerging mechanism programs are restructuring ANCA-associated vasculitis management.
Alopecia areata therapy class competition matures
Baricitinib, ritlecitinib, and deuruxolitinib establish a competitive systemic JAK inhibitor class in severe alopecia areata.
Chimeric autoantibody receptor T cells enter pemphigus vulgaris
Desmoglein 3-targeted CAART cell therapy programs in pemphigus vulgaris are reading out as a precision approach to autoantibody-driven disease.
Lupus nephritis therapy options mature past induction-and-maintenance
Voclosporin and belimumab in lupus nephritis plus emerging mechanism programs are restructuring induction and maintenance therapy.
Hidradenitis suppurativa biologic options widen past TNF
IL-17-class secukinumab and bimekizumab approvals plus emerging novel mechanism programs are restructuring hidradenitis suppurativa management.
Sjogren disease therapy enters real prescribing territory
First positive pivotal readouts in Sjogren disease are establishing a category that has had no specific systemic therapy for decades.
TYK2 inhibitor commercial uptake in psoriasis is reshaping the oral-versus-injection conversation
TYK2 inhibitor uptake in psoriasis is establishing the first commercially meaningful oral biologic alternative for moderate-to-severe disease. The route-of-administration conversation is now active in a way it has not been in the IL-23 and IL-17 era.
IBD biologic sequencing patterns reveal the early-line ustekinumab opportunity
Real-world IBD biologic sequencing data shows ustekinumab and adjacent IL-12/23 mechanisms moving earlier in the line of therapy than the historical anti-TNF-first paradigm. The implications for commercial planning across the IBD biologic class are material.
JAK class label restrictions are reshaping moderate-disease prescribing
FDA boxed warnings and EMA caution have repositioned JAK inhibitors as later-line agents in rheumatoid arthritis, atopic dermatitis, and psoriatic arthritis - reshaping the practical sequencing decision in moderate disease.
Snapshots
6Systemic sclerosis therapy reference (2026)
Reference snapshot of systemic sclerosis therapy across organ-domain-specific and emerging disease-modifying tiers.
ANCA-associated vasculitis therapy reference (2026)
Reference snapshot of ANCA-associated vasculitis therapy across induction, maintenance, and refractory disease.
Lupus nephritis therapy reference (2026)
Reference snapshot of lupus nephritis therapy across induction and maintenance phases.
Sjogren disease therapy reference (2026)
Reference snapshot of Sjogren disease therapy across symptomatic, off-label, and emerging mechanism-targeted tiers.
IBD biologic and small-molecule landscape, 2026 mid-year reference
Reference layout of the IBD therapeutic class as of mid-2026: approved biologics (anti-TNF, anti-integrin, IL-12/23, IL-23), oral small molecules (JAK, S1P modulators, TYK2 in pipeline), and the live commercial questions including line-of-therapy positioning and combination strategy.
Psoriasis biologics landscape, 2026 mid-year reference
Reference layout of the psoriasis biologic class as of mid-2026: approved mechanisms, first-line versus later-line positioning, the IL-23 dominance picture, and the live commercial questions for the class.
Explained
4What is systemic sclerosis?
Plain-language primer on systemic sclerosis (scleroderma), why it affects multiple organ systems, and what modern therapy can offer.
What is ANCA-associated vasculitis?
Plain-language primer on ANCA-associated vasculitis, why it can affect multiple organs, and how modern therapy works.
What is lupus nephritis?
Plain-language primer on lupus nephritis, why kidney involvement is a turning point in lupus, and how modern therapy works.
What is Sjogren disease?
Plain-language primer on Sjogren disease, why it has been hard to treat, and what is changing.